Publications
337 publications
Sort by: Date / Relevance
GVS assessment of amikacin liposome inhalation suspension (Arikayce® liposomal) for the treatment of NTM lung infections
Zorginstituut Nederland has completed its assessment whether amikacin liposome inhalation suspension (Arikayce® liposomal) can be ...
GVS assessment - extension of further conditions for nintedanib (Ofev®)
Zorginstituut Nederland has completed its assessment of the possible extension of the further conditions for nintedanib (Ofev®) ...
Package advice polatuzumab vedotin (Polivy®) in combination with bendamustine and rituximab (Pola-BR) for the treatment of r/r DLBCL
Zorginstituut Nederland has completed its assessment whether polatuzumab vedotin (Polivy®) in combination with bendamustine and ...
GVS assessment of tafamidis (Vyndaqel®) for the treatment of wild-type or hereditary transthyretin amyloidosis
Zorginstituut Nederland has completed its assessment whether tafamidis (Vyndaqel®) for the treatment of wild-type or hereditary ...
Advice on a potential candidate for conditional inclusion of ataluren (Translarna®) for Duchenne's muscular dystrophy
Zorginstituut Nederland recommends that ataluren be designated as a potential candidate for conditional inclusion. Ataluren is ...
GVS advice concerning siponimod (Mayzent®) for the treatment of secondary progressive multiple sclerosis
Zorginstituut Nederland has completed its assessment whether siponimod (Mayzent®) is interchangeable with a product that is ...
Package advice venetoclax (Venclyxto®) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphatic leukaemia (CLL)
Zorginstituut Nederland has completed its assessment whether venetoclax (Venclyxto®) in combination with obinutuzumab for the ...
GVS assessment of glucagon nasal powder (Baqsimi®) for the treatment of severe hypoglycaemia
Zorginstituut Nederland has completed its assessment whether glucagon nasal powder (Baqsimi®) for the treatment of severe ...
GVS assessment of ozanimod (Zeposia®) for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS)
Zorginstituut Nederland has completed its assessment whether ozanimod (Zeposia®) for the treatment of adult patients with ...
GVS assessment of amisulpride (Aktiprol®) for the treatment of schizophrenia
Zorginstituut Nederland has completed its assessment whether amisulpride (Aktiprol®) can be included in the GVS. ...